NovoMix 30 Penfill is a biphasic insulin formulation containing 30% soluble insulin aspart and 70% insulin aspart protamine. This combination provides both rapid and intermediate-acting insulin effects, making it suitable for managing blood glucose levels in individuals with type 1 and type 2 diabetes mellitus. The insulin is produced using recombinant DNA technology, ensuring it is structurally identical to natural human insulin. NovoMix 30 Penfill is administered subcutaneously and is available in a 3 ml cartridge designed for use with insulin pens. It is indicated for the treatment of diabetes, particularly when blood glucose levels cannot be controlled by diet and oral medications alone. The onset of action is within 10 to 20 minutes, with peak effects occurring between 1 and 4 hours, and a duration of action up to 24 hours. Patients should follow their healthcare provider's instructions regarding dosage and administration. Common side effects may include hypoglycemia (low blood sugar), allergic reactions, and injection site reactions. Proper storage and handling are essential to maintain the efficacy of the insulin